EP1572910A4 - Signal for packaging of influenza virus vectors - Google Patents

Signal for packaging of influenza virus vectors

Info

Publication number
EP1572910A4
EP1572910A4 EP20030716017 EP03716017A EP1572910A4 EP 1572910 A4 EP1572910 A4 EP 1572910A4 EP 20030716017 EP20030716017 EP 20030716017 EP 03716017 A EP03716017 A EP 03716017A EP 1572910 A4 EP1572910 A4 EP 1572910A4
Authority
EP
European Patent Office
Prior art keywords
packaging
signal
influenza virus
virus vectors
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP20030716017
Other languages
German (de)
French (fr)
Other versions
EP1572910B1 (en
EP1572910A2 (en
Inventor
Yoshihiro Kawaoka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Priority to EP15197386.4A priority Critical patent/EP3009507B1/en
Publication of EP1572910A2 publication Critical patent/EP1572910A2/en
Publication of EP1572910A4 publication Critical patent/EP1572910A4/en
Application granted granted Critical
Publication of EP1572910B1 publication Critical patent/EP1572910B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP03716017.3A 2002-02-13 2003-02-12 Signal for packaging of influenza virus vectors Expired - Lifetime EP1572910B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP15197386.4A EP3009507B1 (en) 2002-02-13 2003-02-12 Signal for packaging of influenza virus vectors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35653802P 2002-02-13 2002-02-13
US356538P 2002-02-13
US43867903P 2003-01-07 2003-01-07
US438679P 2003-01-07
PCT/US2003/004233 WO2003068923A2 (en) 2002-02-13 2003-02-12 Signal for packaging of influenza virus vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP15197386.4A Division EP3009507B1 (en) 2002-02-13 2003-02-12 Signal for packaging of influenza virus vectors

Publications (3)

Publication Number Publication Date
EP1572910A2 EP1572910A2 (en) 2005-09-14
EP1572910A4 true EP1572910A4 (en) 2008-01-23
EP1572910B1 EP1572910B1 (en) 2015-12-02

Family

ID=34380774

Family Applications (2)

Application Number Title Priority Date Filing Date
EP03716017.3A Expired - Lifetime EP1572910B1 (en) 2002-02-13 2003-02-12 Signal for packaging of influenza virus vectors
EP15197386.4A Expired - Lifetime EP3009507B1 (en) 2002-02-13 2003-02-12 Signal for packaging of influenza virus vectors

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP15197386.4A Expired - Lifetime EP3009507B1 (en) 2002-02-13 2003-02-12 Signal for packaging of influenza virus vectors

Country Status (13)

Country Link
US (3) US7226774B2 (en)
EP (2) EP1572910B1 (en)
JP (1) JP4430942B2 (en)
KR (1) KR101113432B1 (en)
CN (1) CN103540614B (en)
AU (2) AU2003219745B8 (en)
BR (1) BRPI0307679A2 (en)
CA (1) CA2492097C (en)
ES (2) ES2563402T3 (en)
HU (2) HUE050222T2 (en)
IL (2) IL163546A (en)
MX (1) MXPA04007914A (en)
WO (1) WO2003068923A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176021B2 (en) 2001-02-23 2007-02-13 Wisconsin Alumni Research Foundation Mutant cells with altered sialic acid
CN103540614B (en) 2002-02-13 2018-02-02 威斯康星旧生研究基金会 The signal of packaging of influenza virus vectors
MX342639B (en) * 2003-05-28 2016-10-07 Wisconsin Alumni Res Found High titer recombinant influenza viruses for vaccines and gene therapy.
AU2005337178A1 (en) 2004-11-19 2007-04-19 Wisconsin Alumni Research Foundation Recombinant influenza vectors with tandem transcription units
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7790434B2 (en) * 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
RU2008101367A (en) * 2005-06-21 2009-08-10 Медиммун, Ллк (Us) METHODS AND COMPOSITIONS FOR EXPRESSION OF NEGATIVE SENSE VIRAL RNA IN DOGS CELLS
JP2009512449A (en) * 2005-10-19 2009-03-26 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Materials and methods for respiratory disease management in dogs
EP2010557B1 (en) * 2006-03-31 2014-02-26 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
BRPI0710626A2 (en) 2006-04-19 2011-08-16 Medimmune Llc isolated nucleic acid, expression vector, methods for producing an influenza genomic rna and recombinant influenza virus, cell, method for generating in cultured canine cells an rna virus, influenza virus, and, isolated nucleic acid sequence
WO2007130327A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
WO2007130330A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
KR100702034B1 (en) * 2006-05-12 2007-03-30 삼성전자주식회사 Semiconductor device, method of reducing power noise and printed circuit board
WO2008147496A2 (en) * 2007-05-04 2008-12-04 Warf - Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines
WO2008148104A1 (en) * 2007-05-25 2008-12-04 Novavax, Inc. Novel vlps derived from cells that do not express a viral matrix or core protein
RU2499053C2 (en) * 2007-06-15 2013-11-20 Медикаго Инк. Synthesis method of protein with modified profile of n-glycosylation in plants
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
CN101978066A (en) 2007-11-27 2011-02-16 麦迪卡格公司 Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
PT2294202E (en) * 2008-07-08 2015-10-09 Medicago Inc Soluble recombinant influenza antigens
ES2593277T3 (en) * 2008-07-18 2016-12-07 Medicago Inc. New immunization epitope against influenza virus
JP2012521786A (en) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ Influenza virus vaccine and use thereof
NZ597401A (en) * 2009-06-24 2013-09-27 Medicago Inc Chimeric influenza virus-like particles comprising hemagglutinin
WO2011014645A1 (en) * 2009-07-30 2011-02-03 Mount Sinai School Of Medicine Of New York University Influenza viruses and uses thereof
PL2480658T3 (en) 2009-09-22 2017-12-29 Medicago Inc. Method of preparing plant-derived vlps
ES2813347T3 (en) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Recombinant High Titer Influenza Viruses with Enhanced Replication in Vero Cells
KR20120132506A (en) 2010-02-18 2012-12-05 마운트 시나이 스쿨 오브 메디슨 Vaccines for use in the prophylaxis and treatment of influenza virus disease
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
WO2011123495A1 (en) 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
WO2011156273A1 (en) * 2010-06-06 2011-12-15 Mount Sinai School Of Medicine Recombinant rna viruses and uses thereof
TWI620816B (en) 2011-03-23 2018-04-11 苜蓿股份有限公司 Method of recovering plant-derived proteins
EP2747778B1 (en) 2011-08-26 2017-12-06 Wisconsin Alumni Research Foundation Influenza viruses with mutant pb2 gene segment as live attenuated vaccines
US10131695B2 (en) 2011-09-20 2018-11-20 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
CA2895508A1 (en) 2012-12-18 2014-06-26 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
JP2016524915A (en) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション High titer recombinant influenza virus with enhanced replication in MDCK, Vero cells or eggs
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
JP2018504412A (en) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ Influenza virus vaccination regimen
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
WO2017040203A1 (en) 2015-08-28 2017-03-09 Yoshihiro Kawaoka Generation of infectious influenza viruses from virus-like particles
CN109477074B (en) 2016-02-19 2023-01-24 威斯康星旧生研究基金会 Improved influenza b virus replication for vaccine development
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
CN114908122B (en) * 2021-02-07 2024-05-07 广州恩宝生物医药科技有限公司 Novel influenza virus vector for expressing exogenous protein and construction method thereof
CN113069540B (en) * 2021-03-15 2022-02-22 广州恩宝生物医药科技有限公司 Novel coronavirus vaccine based on influenza virus vector and preparation method thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786199A (en) * 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5854037A (en) * 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US6001634A (en) * 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5658772A (en) 1989-12-22 1997-08-19 E. I. Du Pont De Nemours And Company Site-specific recombination of DNA in plant cells
US6843996B1 (en) 1995-06-05 2005-01-18 Medimmune Vaccines, Inc. Immunogenic composition comprising an influenza virus with a temperature sensitive PB2 mutation
US6271011B1 (en) * 1996-10-15 2001-08-07 The University Of Georgia Research Foundation, Inc. Pasteurella neuraminidase coding sequences and diagnostic methods
PT1820853E (en) * 1999-04-06 2012-01-03 Wisconsin Alumni Res Found Recombinant influenza viruses for vaccines and gene therapy
ATE353370T1 (en) 1999-07-14 2007-02-15 Sinai School Medicine IN VITRO RECONSTITUTION OF SEGMENTED NEGATIVE STRAND RNA VIRUSES
WO2001079273A2 (en) * 2000-04-14 2001-10-25 Wisconsin Alumni Research Foundation Viruses comprising mutated ion channel protein
US20040241139A1 (en) * 2000-07-20 2004-12-02 Gerd Hobom Recombinant influenza viruses with bicistronic vRNAs coding for two genes in tandem arrangement
EP1201760A1 (en) 2000-10-30 2002-05-02 ARTEMIS Pharmaceuticals GmbH Influenza virus vector for human dendritic cells
CN103540614B (en) 2002-02-13 2018-02-02 威斯康星旧生研究基金会 The signal of packaging of influenza virus vectors
MX2007005719A (en) 2004-11-11 2007-10-04 Univ Erasmus Medical Ct Defective influenza virus particles.
EP2010557B1 (en) 2006-03-31 2014-02-26 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
WO2008147496A2 (en) 2007-05-04 2008-12-04 Warf - Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [online] EBI, HINXTON, UK; 14 November 2001 (2001-11-14), FIELDS S AND WINTER G: "Nucleotide sequences of influenza virus segments 1 and 3 reveal mosaic structure of small viral RNA segment", XP002459965, Database accession no. NC_002023 *
DUHAUT S D ET AL: "Heterologous Protection of Mice from a Lethal Human H1N1 Influenza A Virus Infection by H3N8 Equine Defective Interfering Virus: Comparison of Defective RNA Sequences Isolated from the DI Inoculum and Mouse Lung", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 248, no. 2, 1 September 1998 (1998-09-01), pages 241 - 253, XP004445692, ISSN: 0042-6822 *
DUHAUT S ET AL: "Approximately 150 Nucleotides from the 5' End of an Influenza A Segment 1 Defective Virion RNA Are Needed for Genome Stability during Passage of Defective Virus in Infected Cells", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 275, no. 2, 30 September 2000 (2000-09-30), pages 278 - 285, XP004435887, ISSN: 0042-6822 *
FUJII YUTAKA ET AL: "Selective incorporation of influenza virus RNA segments into virions.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 18 FEB 2003, vol. 100, no. 4, 18 February 2003 (2003-02-18), pages 2002 - 2007, XP002428351, ISSN: 0027-8424 *
SHINYA KYOKO ET AL: "Characterization of a neuraminidase-deficient influenza a virus as a potential gene delivery vector and a live vaccine.", JOURNAL OF VIROLOGY MAR 2004, vol. 78, no. 6, March 2004 (2004-03-01), pages 3083 - 3088, XP002459964, ISSN: 0022-538X *

Also Published As

Publication number Publication date
US20090311669A1 (en) 2009-12-17
CA2492097C (en) 2013-06-25
CN103540614A (en) 2014-01-29
EP3009507B1 (en) 2020-06-24
WO2003068923A2 (en) 2003-08-21
HUE027448T2 (en) 2016-09-28
IL163546A (en) 2011-02-28
US20070141699A1 (en) 2007-06-21
KR101113432B1 (en) 2012-02-29
EP1572910B1 (en) 2015-12-02
JP4430942B2 (en) 2010-03-10
EP1572910A2 (en) 2005-09-14
AU2003219745B2 (en) 2008-04-17
AU2003219745A1 (en) 2003-09-04
ES2563402T3 (en) 2016-03-15
HUE050222T2 (en) 2020-11-30
AU2003219745B8 (en) 2008-10-09
IL211324A0 (en) 2016-10-31
JP2005535288A (en) 2005-11-24
AU2008203186A1 (en) 2008-08-07
US7226774B2 (en) 2007-06-05
CN103540614B (en) 2018-02-02
MXPA04007914A (en) 2004-10-15
US8298805B2 (en) 2012-10-30
ES2806412T3 (en) 2021-02-17
KR20100065405A (en) 2010-06-16
US20040002061A1 (en) 2004-01-01
CA2492097A1 (en) 2003-08-21
WO2003068923A3 (en) 2006-02-09
BRPI0307679A2 (en) 2016-11-08
WO2003068923A9 (en) 2004-02-12
US7585657B2 (en) 2009-09-08
EP3009507A1 (en) 2016-04-20
IL163546A0 (en) 2005-12-18
AU2008203186B2 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
HUE050222T2 (en) Signal for packaging of influenza virus vectors
GB2431969B (en) Aerosol package
HK1082422A1 (en) Multi plasmid system for the production of influenza virus
AU2003272435A8 (en) Packaging system
DK1394044T3 (en) packaging system
EP1448019A4 (en) Yoke of speaker
HK1075936A1 (en) Vaccine for the prevention of malaria
IL162844A0 (en) Use of an expression vector for preparing pharmaceutical compositions
IL164712A0 (en) Antiviral inhibition of capsid proteins
AU2003295794A8 (en) Modulation of stat2 expression
AUPS137602A0 (en) Viral packaging system
AU155150S (en) Pharmaceutical packaging
AU155083S (en) Pharmaceutical packaging
UA6130S (en) SET OF LABELS FOR PACKAGING
AU2003289990A1 (en) Expression of peptides of the cytoplasmic domain of hiv-gp41 for inhibiting viral infections
AU2002347102A1 (en) Means for inhibition of the synthesis of viral proteins
UA6667S (en) PACKAGE FOR PACKAGING OF BROILERS - CHICKEN
UA7153S (en) LABEL FOR PACKAGING OF WASHING POWDER
AU2003212118A1 (en) Hapatitis b viral packaging system
GB2397813B (en) Article of packaging
AU149189S (en) Set of soap packaging
AU149191S (en) Set of soap packaging
AU149187S (en) Set of soap packaging
AU149188S (en) Set of soap packaging
AU149190S (en) Set of soap packaging

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040906

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/44 20060101ALI20060323BHEP

Ipc: C12P 21/00 20060101ALI20060323BHEP

Ipc: C12N 15/86 20060101ALI20060323BHEP

Ipc: C12N 7/01 20060101AFI20060323BHEP

Ipc: C12N 15/09 20060101ALI20060323BHEP

Ipc: C12N 7/02 20060101ALI20060323BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080102

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WISCONSIN ALUMNI RESEARCH FOUNDATION

17Q First examination report despatched

Effective date: 20081020

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

DAX Request for extension of the european patent (deleted)
INTG Intention to grant announced

Effective date: 20150521

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

INTG Intention to grant announced

Effective date: 20151020

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 763636

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151215

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60348303

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2563402

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20160315

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 763636

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160229

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151202

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151202

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151202

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160303

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151202

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160404

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151202

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60348303

Country of ref document: DE

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E027448

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151202

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160212

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151202

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160229

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160229

26N No opposition filed

Effective date: 20160905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151202

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160212

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: IT

Effective date: 20170710

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151202

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 60348303

Country of ref document: DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20211230

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20220110

Year of fee payment: 20

Ref country code: HU

Payment date: 20220112

Year of fee payment: 20

Ref country code: DE

Payment date: 20211230

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20220209

Year of fee payment: 20

Ref country code: NL

Payment date: 20220118

Year of fee payment: 20

Ref country code: IT

Payment date: 20220111

Year of fee payment: 20

Ref country code: FR

Payment date: 20220118

Year of fee payment: 20

Ref country code: ES

Payment date: 20220303

Year of fee payment: 20

Ref country code: CZ

Payment date: 20220118

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60348303

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20230211

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20230211

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20230426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230212

Ref country code: CZ

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230213